![Page 1: Radiopharmaceuticals for Position Emission Tomography (PET)](https://reader033.vdocuments.us/reader033/viewer/2022050211/626e1ca0cfda377eb325f6c0/html5/thumbnails/1.jpg)
Radiopharmaceuticals
for Position Emission Tomography (PET)
Krzysztof Kilian
University of Warsaw, Heavy Ion Laboratory
• PET characteristics
• Manufacturing of radiopharmaceuticals
• Good Manufacturing Practice
• Radiopharmaceutical Production Site – process management and
design
• Applications
Agenda
![Page 2: Radiopharmaceuticals for Position Emission Tomography (PET)](https://reader033.vdocuments.us/reader033/viewer/2022050211/626e1ca0cfda377eb325f6c0/html5/thumbnails/2.jpg)
• PET characteristics
• Manufacturing of radiopharmaceuticals
• Good Manufacturing Practice
• Radiopharmaceutical Production Site – process management and
design
• Applications
Agenda
Anatomy Physiology Metabolic Molecules
RTG CT USG MRI PET
Positon Tomography PET
X-ray
USG
MRI
Contemporary diagnostics modes
![Page 3: Radiopharmaceuticals for Position Emission Tomography (PET)](https://reader033.vdocuments.us/reader033/viewer/2022050211/626e1ca0cfda377eb325f6c0/html5/thumbnails/3.jpg)
Some definitions
Radiotracer - chemical compound consists of:
Radioisotope: a radionuclide with physical data suitable for
external measurement
Linker : a molecule with suitable pharmacokinetics, and high
concentrations in the target organ or process
Some definitions
Radiotracer - chemical compound consists of:
Radioisotope: a radionuclide with physical data suitable for
external measurement
Linker : a molecule with suitable pharmacokinetics, and high
concentrations in the target organ or process
![Page 4: Radiopharmaceuticals for Position Emission Tomography (PET)](https://reader033.vdocuments.us/reader033/viewer/2022050211/626e1ca0cfda377eb325f6c0/html5/thumbnails/4.jpg)
PET Characteristics
• 3D imaging mode with ß-isotopes
PET Characteristics
Linear resolution in clinical imaging [mm]:
• CT: 0.5-1.0
• MRI: 0.2-
• USG: 0.1-1
• PET: 3-6
![Page 5: Radiopharmaceuticals for Position Emission Tomography (PET)](https://reader033.vdocuments.us/reader033/viewer/2022050211/626e1ca0cfda377eb325f6c0/html5/thumbnails/5.jpg)
PET Characteristics
Linear resolution in clinical imaging [mm]:
• CT: 0.5-1.0
• MRI: 0.2-
• USG: 0.1-1
• PET: 3-6
• Coupling PET with anatomic imaging modes
PET Characteristics
+ =
![Page 6: Radiopharmaceuticals for Position Emission Tomography (PET)](https://reader033.vdocuments.us/reader033/viewer/2022050211/626e1ca0cfda377eb325f6c0/html5/thumbnails/6.jpg)
• PET characteristics
• Manufacturing of radiopharmaceuticals
• Good Manufacturing Practice
• Radiopharmaceutical Production Site – process management and
design
• Applications
Agenda
• 18F – half-life 110 min.
• 11C - half-life 20 min.
• 15O - half-life 2 min.
• 13N - half-life 10 min.
PET Radioisotopes
Useful radionuclides
Radionuclide scissors
• Shorter halflife – radiation exposure
• Longer halflife – clinical availability
![Page 7: Radiopharmaceuticals for Position Emission Tomography (PET)](https://reader033.vdocuments.us/reader033/viewer/2022050211/626e1ca0cfda377eb325f6c0/html5/thumbnails/7.jpg)
Isotopes production
Cyclotrone IBA 18/9 Cyclotrone GE PETrace 8
Cyclotrone
Targets
Target for liquids Target for gases
![Page 8: Radiopharmaceuticals for Position Emission Tomography (PET)](https://reader033.vdocuments.us/reader033/viewer/2022050211/626e1ca0cfda377eb325f6c0/html5/thumbnails/8.jpg)
18F Production
Production18F :
Reaction: 18O(p,n)18F
Target: H218O c, 95%18O
Product: 18F–
Target for liquids
18F Production
Production18F :
Reaction : 18O(p,n)18F
Target : 18O g, 95%18O
Product : F2 (18F19F)
Target for gases
![Page 9: Radiopharmaceuticals for Position Emission Tomography (PET)](https://reader033.vdocuments.us/reader033/viewer/2022050211/626e1ca0cfda377eb325f6c0/html5/thumbnails/9.jpg)
11C Production
Production 11C :
Reaction : 14N(p,α)11C
Target : 99,6%14N (0,1-5%H2)
Product : HCN, CH4
or
Target : 14N (O2)
Product : CO, CO2
Target for gases
15O Production
Production 15O :
Reaction : 14N(d,n)15O
Target : 99%natN2 + 1% 16O2
Product : 15O16O
Target for gases
![Page 10: Radiopharmaceuticals for Position Emission Tomography (PET)](https://reader033.vdocuments.us/reader033/viewer/2022050211/626e1ca0cfda377eb325f6c0/html5/thumbnails/10.jpg)
Radiopharamceuticals manufacturing
Automatic units
KRYPTOFIX SPE ACN PRECURSOR WATER
INLET F18
RECOVERY
H2O18
STERILE FILTER 0.22µ
STERILE FILTER 0.22µ
NaOH
pH
Al2O3
C18
OUTLET
FDG
INLET N2
REACTOR
REACTOR
VACUUM
Radiopharamceuticals manufacturing
![Page 11: Radiopharmaceuticals for Position Emission Tomography (PET)](https://reader033.vdocuments.us/reader033/viewer/2022050211/626e1ca0cfda377eb325f6c0/html5/thumbnails/11.jpg)
Radiopharamceuticals manufacturing
Dispensing
Radiopharamceuticals manufacturing
![Page 12: Radiopharmaceuticals for Position Emission Tomography (PET)](https://reader033.vdocuments.us/reader033/viewer/2022050211/626e1ca0cfda377eb325f6c0/html5/thumbnails/12.jpg)
• PET characteristics
• Manufacturing of radiopharmaceuticals
• Good Manufacturing Practice
• Radiopharmaceutical Production Site – process management and
design
• Applications
Agenda
GMP
![Page 13: Radiopharmaceuticals for Position Emission Tomography (PET)](https://reader033.vdocuments.us/reader033/viewer/2022050211/626e1ca0cfda377eb325f6c0/html5/thumbnails/13.jpg)
GMP
Manufacturing regulations
![Page 14: Radiopharmaceuticals for Position Emission Tomography (PET)](https://reader033.vdocuments.us/reader033/viewer/2022050211/626e1ca0cfda377eb325f6c0/html5/thumbnails/14.jpg)
Radiopharmaceutical site structure
1. Isotope production
2. Synthesis
3. Final sterility
4. Quality control
Cleanrooms
![Page 15: Radiopharmaceuticals for Position Emission Tomography (PET)](https://reader033.vdocuments.us/reader033/viewer/2022050211/626e1ca0cfda377eb325f6c0/html5/thumbnails/15.jpg)
Cleanrooms
Cleanrooms
![Page 16: Radiopharmaceuticals for Position Emission Tomography (PET)](https://reader033.vdocuments.us/reader033/viewer/2022050211/626e1ca0cfda377eb325f6c0/html5/thumbnails/16.jpg)
Isolator safety features
Dispensing unit
![Page 17: Radiopharmaceuticals for Position Emission Tomography (PET)](https://reader033.vdocuments.us/reader033/viewer/2022050211/626e1ca0cfda377eb325f6c0/html5/thumbnails/17.jpg)
Quality control
1. Isotope production
2. Synthesis
3. Final sterility
4. Quality control
Quality control
![Page 18: Radiopharmaceuticals for Position Emission Tomography (PET)](https://reader033.vdocuments.us/reader033/viewer/2022050211/626e1ca0cfda377eb325f6c0/html5/thumbnails/18.jpg)
Application in medicine and science
Oncology
Tumor diagnostics:
•Evaluation of the nature of the change
•Diagnosis and staging of cancer
•Monitoring during and after treatment
•Radiotherapy planning
Application in medicine
Oncology
Evaluation of the the change
CT PET
![Page 19: Radiopharmaceuticals for Position Emission Tomography (PET)](https://reader033.vdocuments.us/reader033/viewer/2022050211/626e1ca0cfda377eb325f6c0/html5/thumbnails/19.jpg)
Application in medicine
Oncology
Diagnosis and staging of cancer
Application in medicine
Oncology
Monitoring during and after treatment
Before
After
![Page 20: Radiopharmaceuticals for Position Emission Tomography (PET)](https://reader033.vdocuments.us/reader033/viewer/2022050211/626e1ca0cfda377eb325f6c0/html5/thumbnails/20.jpg)
Application in medicine
Oncology
Radiotherapy planning :
CT
PET
PET + CT Therapy
Application in medicine
Oncology
Principles:
• increased glycolysis in tumor cells – Warburg phenomenon – 20-
30-times higher glucose metabolism
• increased permeability of biological membranes of tumor cells
• increased protein synthesis
• specific reactions
![Page 21: Radiopharmaceuticals for Position Emission Tomography (PET)](https://reader033.vdocuments.us/reader033/viewer/2022050211/626e1ca0cfda377eb325f6c0/html5/thumbnails/21.jpg)
Application in medicine
Oncology
Principle:
• increased glycolysis in tumor cells – Warburg phenomenon – 20-
30-times higher glucose metabolism
18F-FDG (2-Deoxy-2-fluoro-D-glucose )
Standard radiopharamceutic in clinical practice: diagnosis of most cancers
Application in medicine
Oncology
Principle:
•increased permeability of biological membranes of tumor cells
18F-choline11C -choline
Diagnosis of prostate cancer
![Page 22: Radiopharmaceuticals for Position Emission Tomography (PET)](https://reader033.vdocuments.us/reader033/viewer/2022050211/626e1ca0cfda377eb325f6c0/html5/thumbnails/22.jpg)
Application in medicine
Oncology
Principle :
•increased protein synthesis
18F -thymidine 11C -metionine18F-methylotyrosine
Brain cancer, others as suplementary tracers
Application in medicine
Oncology
Principle:
•Specific reactions
18F-MISO
Diagnosis of hypoxia
![Page 23: Radiopharmaceuticals for Position Emission Tomography (PET)](https://reader033.vdocuments.us/reader033/viewer/2022050211/626e1ca0cfda377eb325f6c0/html5/thumbnails/23.jpg)
Application in medicine
Neurology
•Brain cancer diagnostics
•Diagnosis and staging of dementia (AD) and movement disorders (PD)
•Neuroactivation
Cardiology
Diagnosis and evaluation of heart : 13NH3, 18F-FDG, 11C-palmitate
Application in science nad R&D
AnimalPET
• Drug discovery
•Clinical studies
![Page 24: Radiopharmaceuticals for Position Emission Tomography (PET)](https://reader033.vdocuments.us/reader033/viewer/2022050211/626e1ca0cfda377eb325f6c0/html5/thumbnails/24.jpg)
All-in-one systems with generators
Transport
Costs
Simplicity
Application in science nad R&D
Application in science nad R&D
Available generators
• 68Ga - halflife 67,8 min.
• 82Rb - halflife 1,26 min.
• 94Tc - halflife 53 min.
• 122I - halflife 3,6 min.
• 124Tc - halflife 4,15 dni
![Page 25: Radiopharmaceuticals for Position Emission Tomography (PET)](https://reader033.vdocuments.us/reader033/viewer/2022050211/626e1ca0cfda377eb325f6c0/html5/thumbnails/25.jpg)
Application in science nad R&D
ImmunoPET
124I, 89Zr – PET radiotracers (t1/2 ca 80-100h), labelling MAB
(monoclonal antibodies)
211At – alfa emiter for tratment
Bone marrowBone surface
Bone
Tumour
Range ββββ particle
Range αααα particle
ββββ-emitter
Range Auger electrons
Application in science nad R&D
![Page 26: Radiopharmaceuticals for Position Emission Tomography (PET)](https://reader033.vdocuments.us/reader033/viewer/2022050211/626e1ca0cfda377eb325f6c0/html5/thumbnails/26.jpg)
• PET characteristics
• Manufacturing of radiopharmaceuticals
• Good Manufacturing Practice
• Radiopharmaceutical Production Site – process management and
design
• Applications
Summary
Concluding remark
![Page 27: Radiopharmaceuticals for Position Emission Tomography (PET)](https://reader033.vdocuments.us/reader033/viewer/2022050211/626e1ca0cfda377eb325f6c0/html5/thumbnails/27.jpg)
Radiopharmaceuticals
for Position Emission Tomography (PET)
Krzysztof Kilian
University of Warsaw, Heavy Ion Laboratory